Rivia lands $15M to transform clinical trial data with AI
Healthtech startup Rivia has raised $15 million in fresh funding to build an AI engine designed to make sense of the vast, fragmented universe of clinical trial data. The company aims to give pharmaceutical firms, biotech startups and research institutions a single, intelligent layer for searching, comparing and reusing trial insights that are currently scattered across PDFs, registries and proprietary databases.
Turning unstructured clinical data into a strategic asset
Rivia is developing a platform that uses advanced natural language processing and domain-specific machine learning models to ingest, standardise and enrich trial information. By converting unstructured reports, protocols and outcomes into a structured knowledge graph, the startup wants to cut weeks or months from the time researchers spend manually reviewing prior studies.
The system is being built to support complex queries, such as comparing inclusion criteria across competing trials, identifying under‑served patient subgroups, or spotting historical safety signals that could affect new study designs. For sponsors and contract research organizations (CROs), this promises faster feasibility assessments, more precise protocol design and better site selection.
Funding to scale product, data coverage and regulatory-grade quality
The new capital will be used to expand Rivia‘s engineering and data science teams, deepen coverage of global clinical trial registries and peer‑reviewed literature, and harden the platform for use in highly regulated environments. The company is prioritising compliance with GxP expectations and alignment with FDA and EMA guidance on the use of real‑world data and advanced analytics.
By offering audit trails, version control and transparent model behaviour, Rivia aims to ensure its AI algorithms can be trusted in workflows that influence regulatory submissions and high‑stakes clinical decisions. The startup also plans integrations with existing electronic data capture (EDC), clinical trial management systems (CTMS) and data warehouses, positioning its engine as an intelligence layer rather than a replacement for incumbent infrastructure.
Rising demand for AI in drug development
The funding round underscores investor confidence in the growing market for AI‑powered drug development tools. With the cost of bringing a new therapy to market often exceeding billions of dollars, any technology that can reduce protocol amendments, failed trials or recruitment delays is drawing attention from both strategic and financial backers. Rivia is betting that mastering the messy reality of clinical trial data will become a core competitive edge for the next generation of pharmaceutical innovation.